Pre-IPO shareholders sell 9.3% of Cosmo Pharmaceuticals

Shares in Cosmo Pharmaceuticals, the Swiss pharmaceutical company focused on gastrointestinal and skin disorders, fell 6.4% on Friday after a group of pre-IPO shareholders sold 9.3% of the company for Sfr216m through an accelerated bookbuild led by Berenberg.